{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:27:59Z","timestamp":1766053679722,"version":"3.48.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.amjcard.2025.07.040","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:31:07Z","timestamp":1754429467000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent"],"prefix":"10.1016","volume":"257","author":[{"given":"Janos","family":"Molnar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-6203","authenticated-orcid":false,"given":"John C.","family":"Somberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.amjcard.2025.07.040_bib0001","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.3390\/jcm13206094","article-title":"Amiodarone therapy: updated practical insights","volume":"13","author":"\u0218orodoc","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2025.07.040_bib0002","unstructured":"BETAPACE- sotalol hydrochloride tablet \u2013 Drug product label. Accessed June 9, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=afce2787-8899-4098-87c8-f1e8dd19e6dd."},{"issue":"3","key":"10.1016\/j.amjcard.2025.07.040_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000316050","article-title":"QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol","volume":"116","author":"Somberg","year":"2010","journal-title":"Cardiology"},{"issue":"13","key":"10.1016\/j.amjcard.2025.07.040_bib0004","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/0002-9149(86)90692-2","article-title":"Concentration-dependent pharmacologic properties of sotalol","volume":"57","author":"Wang","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.040_bib0005","unstructured":"Tikosyn_Product_Monograph. Accessed June 9, 2025. https:\/\/studylib.net\/doc\/8817030\/tikosyn--dofetilide--product-monograph."},{"issue":"7","key":"10.1016\/j.amjcard.2025.07.040_bib0006","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1592\/phco.20.9.776.35208","article-title":"Dofetilide, a new class III antiarrhythmic agent","volume":"20","author":"Lenz","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.amjcard.2025.07.040_bib0007","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2125.2000.00243.x","article-title":"The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing","volume":"50","author":"Allen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2025.07.040_bib0008","unstructured":"TIKOSYN \u2013 dofetilide- Drug product label. Accessed June 9, 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020931s012s013lbl.pdf"},{"issue":"10","key":"10.1016\/j.amjcard.2025.07.040_bib0009","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/CIRCULATIONAHA.106.180200","volume":"115","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjcard.2025.07.040_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.1991.tb05572.x","article-title":"Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug","volume":"31","author":"Sedgwick","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"10.1016\/j.amjcard.2025.07.040_bib0011","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/0002-9149(92)90295-A","article-title":"Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris","volume":"70","author":"Sedgwick","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.07.040_bib0012","unstructured":"FDA Guidance for Industry E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed June 9, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0."},{"issue":"2","key":"10.1016\/j.amjcard.2025.07.040_bib0013","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2002.01627.x","article-title":"The significance of QT interval in drug development","volume":"54","author":"Shah","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.amjcard.2025.07.040_bib0014","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/00005344-199220002-00015","article-title":"Dofetilide, a novel class III antiarrhythmic agent","volume":"20","author":"Rasmussen","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.07.040_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vascn.2005.07.002","article-title":"Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs","volume":"53","author":"Ollerstam","year":"2006","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"8","key":"10.1016\/j.amjcard.2025.07.040_bib0016","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0002-9149(99)00927-3","article-title":"Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter","volume":"85","author":"Lindeboom","year":"2000","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.07.040_bib0017","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0735-1097(96)00506-2","article-title":"Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators","volume":"29","author":"Falk","year":"1997","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:23:42Z","timestamp":1766053422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925004503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":17,"alternative-id":["S0002914925004503"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.040","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}